Speakers

Kristin Peck

Robert Kelly

Matt Dobbs

Vinicius Chiappetta

Jamie Brannan

Julia Stephanus

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

Sven Arnouts

Lawrence Brown

Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.

Karolina Zapadka

Richard Casey

Jamie Stein

Linda Rhodes

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Katrina Hayter

Andre Jordao

Andre is an experienced entrepreneur and the CEO of Barkyn, a pet food subscription combining personalised food and telemedicine, growing in multiple European countries.

Julie Fitzpatrick

Jon Lowe

Julie Lawless

Apryle Horbal

Christie Chavis

Laëtitia Gerbe

Greg Blair

Brian Lindsay

Deborah Dullen

Sven Smit

Greg Michel

John Kirkpatrick

Edgar Goluch

Marie-Paul Lachaud

Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.

Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development. 

From 2000 to 2008, Dr. Lachaud was the European animal health director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on drug clinical development and regulatory affairs, which was acquired by ICON in 2000. 

Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine for years. Her work has resulted in significant animal health product approvals in Europe and the United-States for companion animals in a number of innovative therapeutic areas, including reproduction, chronic heart failure, chronic kidney disease, pain management, oncology and neurobehavioral disorders. 

She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.

Matthieu Frechin

Stephen Lesser

Rimma Driscoll

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.

Juan-Carlos Carrillo Peláez

Adrienne Woodward

Udi Cohen

Laurie Hueneke

Aaron Schacht

Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Candise Goodwin

Andrew Van Kessel

Sabine Koelle

Dr. David Hodges

Charles Cosgrave

Andrea Iucci

Oliver Boucher

Oliver Boucher has a successful track record creating and managing start-ups and executing strategic transactions at Board level on both the buy-side and sell-side of the life science business-to-business (B2B) market within the pharmaceutical and diagnostics industries. He also has significant experience in fund-raising, both dilutive and non-dilutive. He has held senior commercial and business roles in a succession of biotech companies after having gained executive level experience for seven years as a director of business development at GSK. Before joining industry, Oliver Boucher was a patent attorney in London, Montreal and Paris. He received an MA in genetics and molecular biology from Cambridge University and earned an MBA from INSEAD Business School. Mr Boucher joined Zoetis in 2017.

Sioned Timothy

Daniella Morgan-Pascualvaca

Philip Grose

Steve Maughan

Martin Borchert

Jonathan Hunt

Qi Li

James Wright

Carel du Marchie Sarvaas

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University